Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Top Cited Papers
- 1 May 2015
- journal article
- research article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 3 (5), 355-366
- https://doi.org/10.1016/s2213-2600(15)00042-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Anti-interleukin-5 therapy in severe asthmaEuropean Respiratory Review, 2013
- Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled TrialsPLOS ONE, 2013
- Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patientsJournal of Allergy and Clinical Immunology, 2012
- How safe are the biologicals in treating asthma and rhinitis?Allergy, Asthma & Clinical Immunology, 2009
- Review: Tissue remodeling and angiogenesis in asthma: the role of the eosinophilTherapeutic Advances in Respiratory Disease, 2008
- IL-5 and eosinophiliaCurrent Opinion in Immunology, 2008
- Pulmonary biology of anti-interleukin 5 antibodiesMemórias do Instituto Oswaldo Cruz, 1997
- Structure and humanization of a rat monoclonal Fab to human interleukin-5Protein Engineering, Design and Selection, 1996
- Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthmaClinical and Experimental Allergy, 1995
- Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax, 1992